TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06736704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNV4818
Description: SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNV4818
Description: SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Study: NCT05689060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulling Straight leg raising technique
Description: Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post facilitation stretch
Description: Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
Study: NCT05139030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome injectable suspension
Description: Adductor canal block with EXPAREL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome injectable suspension
Description: Adductor canal block with EXPAREL
Study: NCT05950035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Description: WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi)
Description: CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Nightmares (CBTn)
Description: CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Waitlist for delayed intervention.
Study: NCT06278844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing. In the usual care group, the right ventricular lead will be placed in the right ventricle apex as usual.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular apical pacing
Description: This is the usual care group. Patients will receive a pacemaker device with the right ventricular lead inserted in the apex and not in the septal position.
Study: NCT04547920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Bladder Modulation System-1x per week
Description: Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Bladder Modulation System - 3x per week
Description: Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation
Study: NCT05503069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions with social and cultural components
Description: Intervention Components~* Enrollment: We are expecting an enrollment rate of 20 participants per week, and completing enrollment in 6 weeks (n=120 participants)~* Baseline Data Collection~* Distribution of Educational Materials~* Lactation Training~* Dietary Literacy Training~* Follow Up Data collection: Infant's information on growth and development and Medical History of Infections, GI problems (diarrhea, constipation, colic, vomits, reflux) will be collected at 3, 6 and 12 months.~* Follow UP Surveys: Mothers will complete a short survey at 3, 6, and 12 months exploring their breastfeeding behaviors and challenges.~* Exit survey: Mothers will be asked to complete an exit survey on month 12 post-enrollment to explore their perception on the participation in the study.
Study: NCT04647890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT011
Description: Two x 100mg capsules once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT011
Description: Two x 200mg capsules once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules once daily for 12 weeks
Study: NCT06246279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation to Adolescence and Type 1 Diabetes Management Training Program
Description: The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
Study: NCT05969171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofantinib、abraxane、gemcitabine
Description: The combination of 3 weeks was a treatment cycle, and AG chemotherapy was defined as a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other criteria for discontinuation of study therapy were met in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane combined with gemcitabine
Description: Abraxane combined with gemcitabine
Study: NCT04519177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Education Program (SHEP)
Description: Sleep Health Education Program (SHEP) including screening for common sleep disorders
Study: NCT04604691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab for Injection
Description: Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
Study: NCT06458075

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CO-LEAD
Description: The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
Study: NCT04879979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT
Description: MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
Study: NCT06080139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refugee parenting education in a participatory community
Description: Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Refugee parenting education in a participatory community
Description: Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas.
Study: NCT05088655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
Study: NCT05139030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Adductor Canal Block with bupivacaine HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Adductor Canal Block with bupivacaine HCl
Study: NCT05715216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etigilimab
Description: Given by IV (vein)
Study: NCT06736704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
Study: NCT06737406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 5% fluorouracil cream
Description: Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 5% fluorouracil cream
Description: Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 0.005% calcipotriol ointment
Description: Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 0.005% calcipotriol ointment
Description: Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)
Study: NCT05278091

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observationnal study

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observationnal study

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observationnal study
Study: NCT05694585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
Study: NCT05031221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga + behavioral weight loss
Description: A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
Study: NCT05009082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: 200 or 300 mg capsules once daily for up to a total of 3 years
Study: NCT06737406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo cream in identical tubes in terms of color and scent and with identical usage instructions to fluorouracil.
Study: NCT04913298

Intervention type: DEVICE
Group type: OTHER
Intervention: Cytosorb therapy
Description: Start of Cytosorb therapy is at the discretion of the attending physician
Study: NCT06739564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICE PACKING
Description: ICE PACKING ON LOWER LIMB AFTER AN EXHAUSTION EFFORT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DRY NEEDLING
Description: DRY NEEDLING ON LOWER LIMB AFTER AN EXHAUSTION TRIAL
Study: NCT06739980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Study: NCT06475378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moonbird
Description: Moondbird is a technology-supported breathing exercise with a tactile breath pacer device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
Study: NCT06480955

Intervention type: DEVICE
Intervention: Cryoablation system
Description: Any cryoablation system from Boston Scientific that has received CE Mark and/or FDA clearance for the ablation of bone malignancies.
Study: NCT06370975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% hypertonic Saline
Description: the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's lactated solution
Description: the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Normal saline
Description: the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Study: NCT04120779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The EMPOWER-SUSTAIN e-Health Self-Management Intervention
Description: Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
Study: NCT05009082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: 200 or 300 mg capsules once daily for up to a total of 3 years
Study: NCT05573815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BT-M01
Description: Clinical decision support system for detecting brain metastasis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BT-M01
Description: Clinical decision support system for detecting brain metastasis
Study: NCT04046861

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ascorbic acid,
Description: The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
Study: NCT05747690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIO015
Description: Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIO015
Description: Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
Study: NCT05855356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: respiratory physiotherapy, personalized aerobic and strength training
Study: NCT04023708

Intervention type: DRUG
Intervention: CYD-TDV Dengue Vaccine
Description: Pharmaceutical form:Solution Route of administration: Intramuscular
Study: NCT05855356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Behavioural and Medical management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Behavioural and Medical management